Affiliation:
1. Merck & Co., Inc., Rahway, NJ 07065, USA
2. Ontada, The Woodlands, TX 77380, USA
Abstract
Aim: This study examined real-world treatment patterns for extensive-stage small-cell lung cancer (ES-SCLC) after immune checkpoint inhibitors (ICIs) became available for frontline use. Methods: Adult patients with ES-SCLC initiating 1L systemic treatment were identified from electronic health records. Results: Among patients with recurrent/progressive ES-SCLC, the most common treatment classes were platinum-based chemotherapy (81.1% of 228) and ICI monotherapy (35.1% of 191) in 1L and 2L, respectively. Among patients with de novo ES-SCLC, the most common treatment classes were ICI + platinum-based chemotherapy (64.4% of 1268) and other chemotherapy (44.9% of 512) in 1L and 2L, respectively. Among patients who received no ICI in 1L, 62.6%–70.3% received it in 2L and 62.6–68.5% in 3L. Some who received 1L ICI were re-treated with ICI in subsequent lines (14.5–18.8% in 2L, 18.2–50.0% in 3L). Conclusion: Real-world ICI utilization in ES-SCLC, particularly ICI re-challenge, demonstrates high unmet needs in this patient population.
Subject
Oncology,Immunology,Immunology and Allergy
Reference35 articles.
1. Cancer statistics, 2022
2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Small cell carcinoma of the Lung and Bronchus. Recent trends in SEER Age-Adjusted Incidence Rates, 2015–2019. (2019). https://seer.cancer.gov/explorer/application.html?site=611&data_type=1&graph_type=4&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&race=1&age_range=1&advopt_precision=1
3. Initial Management of Small-Cell Lung Cancer (limited- and Extensive-Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy: A Systematic Review
4. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献